The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy.
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst); Genentech/Roche; Target Pharmasolutions; Target Pharmasolutions (Inst)
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Exelixis (Inst); Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Regeneron (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Tekmira (Inst)
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Genentech/Roche; Lilly
Consulting or Advisory Role - AstraZeneca; Bayer Schering Pharma; BeiGene; Bristol-Myers Squibb; CSR Pharma; Eisai; Genentech/Roche; MSD; Novartis; Ono Pharmaceutical
 
Fadi S. Braiteh
Stock and Other Ownership Interests - Agios; Bristol-Myers Squibb; Clovis Oncology; Insys Therapeutics; Tesaro
Honoraria - Abbott Nutrition; Amgen; ARIAD; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; HERON; Incyte; Insys Therapeutics; Insys Therapeutics; Ipsen; Lexicon; Lilly; Taiho Pharmaceutical
Consulting or Advisory Role - Ambry Genetics; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Incyte; Insys Therapeutics; Ipsen; Ipsen; Lexicon; Lilly; Merck; Merrimack; Pfizer; Regeneron; Sanofi
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Incyte; Insys Therapeutics; Ipsen; Lilly; Merck; Merck; Merrimack; Pfizer; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Bayer; Bayer/Onyx; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Exelixis; HERON; Incyte; Insys Therapeutics; Ipsen; Lexicon; Merrimack; Novartis; Pfizer; Regeneron; Roche/Genentech; Sanofi; Taiho Pharmaceutical; Tesaro
 
Joong-Won Park
Honoraria - Bayer; Bristol-Myers Squibb
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Merck; Ono Pharmaceutical
 
Fawzi Benzaghou
Employment - Ipsen
Stock and Other Ownership Interests - Ipsen
 
Steven Milwee
Employment - Exelixis
Stock and Other Ownership Interests - Amgen; Exelixis; FibroGen; GlaxoSmithKline
 
Anne Borgman
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Anthony B. El-Khoueiry
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Genentech; GlaxoSmithKline
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche
Speakers' Bureau - Merrimack
Research Funding - Astex Pharmaceuticals
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Bristol-Myers Squibb; Genentech; GlaxoSmithKline
 
Zeid K Kayali
No Relationships to Disclose
 
Andrew X. Zhu
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Lilly; Merck; Novartis; Roche/Genentech
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
 
Lorenza Rimassa
Honoraria - Abbvie; AstraZeneca; Gilead Sciences; Roche
Consulting or Advisory Role - Amgen; ArQule; Baxter; Bayer; Celgene; Eisai; Exelixis; Incyte; Ipsen; Italfarmaco; Lilly; Sanofi; Sirtex Medical
Travel, Accommodations, Expenses - ArQule; Ipsen